Medpace Holdings (MEDP) Osake Kurssi
Medpace Holdings Kurssi
Viimeisten 12 vuoden aikana Medpace Holdingsn liikevaihto kasvoi 20,4 % vuodessa ja ylsi 2,53 Mrd. USD:een. Osakekohtainen tulos on kasvanut 26,2 % vuodessa viimeisten 12 vuoden aikana. Medpace Holdingsn nettomarginaali 17,8 % on noussut verrattuna 15,9 %:iin muutama vuosi sitten. Medpace Holdingsn 12 kuukauden konsensustavoitehinta on 610,00 USD, noin ali kurssia 1,8 %. 20 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Pidä.
Medpace Holdings osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Medpace Holdings liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Medpace Holdings -osakkeesta
Medpace Holdings Inc is a clinical contract research organization (CRO) that provides services to pharmaceutical, biotechnology, and medical device companies. The company's business model revolves around offering comprehensive clinical trial management services, including protocol and study design, site selection and management, data management, and regulatory consulting. Medpace's CRO expertise enables efficient and successful execution of clinical trials in various therapeutic areas. With a focus on quality, accuracy, and compliance, Medpace is committed to facilitating the development of innovative pharmaceutical products to improve patient care.
Medpace Holdings Inc is primarily active in the contract research organization (CRO) industry. As a leading global CRO, Medpace provides various services to support the development of pharmaceutical, biotechnology, and medical device products. With its expertise in clinical research, regulatory affairs, and medical writing, Medpace assists companies in navigating the complex process of bringing new therapies to market. Additionally, Medpace works across a range of therapeutic areas, including cardiovascular, oncology, neurology, and infectious diseases. Through its comprehensive services and industry experience, Medpace contributes to advancements in healthcare by facilitating the efficient and innovative development of new medical treatments and therapies.
The main competitors of Medpace Holdings Inc in the market include PRA Health Sciences, ICON plc, and Syneos Health.
Medpace Holdings Inc. is a pharmaceutical contract research organization that provides comprehensive clinical research services to the biotechnology, pharmaceutical, and medical device industries. Founded in 1992 by Dr. August Troendle, Medpace has since grown to become a leading global player in the clinical research industry. With a focus on developing innovative and efficient drug development strategies, Medpace offers services ranging from site feasibility assessments to full-service clinical trial management. The company's team of experienced industry professionals and its commitment to quality and timeliness have propelled Medpace to great success in its mission to accelerate the development of safe and effective medical therapies.
Medpace Holdings Inc, a leading clinical research organization, has achieved notable milestones. The company successfully completed its initial public offering (IPO) in August 2016, marking a significant milestone in its growth trajectory. Medpace has consistently demonstrated its commitment to quality and innovation, which led to its inclusion in the S&P SmallCap 600 Index in 2018. Furthermore, the company expanded its global footprint by establishing offices in Australia, Singapore, and South Korea. Medpace's dedication to advancing medical research and providing exceptional services has earned it recognition as a top CRO (Contract Research Organization) by industry publications.
Medpace Holdings Inc is primarily present in various countries and regions worldwide. With a global presence, Medpace operates in North America, Europe, Asia-Pacific, and other emerging markets. The company has established offices and clinical research sites in numerous countries, including the United States, Canada, France, Germany, Belgium, the Netherlands, India, China, Japan, Singapore, and Australia. Being a leading clinical contract research organization, Medpace collaborates with pharmaceutical, biotechnology, and medical device companies across these regions to provide high-quality clinical research services.
Medpace Holdings Inc represents a strong commitment to quality, integrity, and innovation in the clinical research industry. As a leading global contract research organization (CRO), Medpace is dedicated to providing high-quality, comprehensive services to pharmaceutical and biotechnology companies. The company follows a customer-centric approach and strives to exceed expectations by delivering customized solutions tailored to each client's needs. Medpace emphasizes collaboration, transparency, and scientific excellence in its operations, fostering partnerships with clients and prioritizing the advancement of medical breakthroughs. With its robust corporate philosophy, Medpace continues to drive advancements in drug development and shape the future of clinical research.
Analyytikot asettavat tällä hetkellä Medpace Holdings-osakkeelle keskimääräisen tavoitehinnan 606,38 USD (mediaani: 610,00 USD), mikä merkitsee −2,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.
20 analyytikkoa arvioi tällä hetkellä Medpace Holdings-osaketta: 7 suosittaa ostoa, 12 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Medpace Holdings-yhtiöltä 2,85 Mrd. USD liikevaihtoa ja 17,13 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Medpace Holdings-osake noteerataan hintaan 552,47 EUR (621,09 USD).
Medpace Holdings-osake (MEDP) on listattuna 4 pörssissä, muun muassa: NASDAQ (MEDP), Frankfurt (01P), München (01P.MU), Düsseldorf (01P.DU).
Medpace Holdings Inc. is a leading company in the clinical research industry. The company offers a wide range of clinical study services to its customers in the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Cincinnati, Ohio, USA and has more than 4,500 employees in 47 countries worldwide. Medpace operates its business through three segments: 1. Medpace Clinical Pharmacology Services (MCPS) 2. Medpace Research Operations (MRO) 3. Medpace Medical Device Division (MDD) Medpace Clinical Pharmacology Services (MCPS) is responsible for conducting phase I studies, which aim to test the safety and tolerability of new drugs, vaccines, or other therapies. Small groups of healthy volunteers are studied in a clinical setting to collect data that can later be used in advanced studies to evaluate the effectiveness of a product. Medpace Research Operations (MRO) covers a broader range of clinical studies, such as phase II, phase III, and post-marketing studies. The focus here is to assess the effectiveness and safety of drugs or medical devices in a larger number of patients. Medpace Medical Device Division (MDD) offers a wide range of services for evaluating the safety and effectiveness of medical devices and implants. The company employs a group of experienced experts who help in the development and conduct of clinical studies involving medical devices and implants. Medpace also offers its customers a variety of supportive services, such as data management, biostatistics, and medical monitoring. The company has also developed its own electronic data management platform, which provides a high level of efficiency and accuracy in conducting clinical studies. It is worth mentioning that Medpace does not offer products in the traditional sense. Instead, the services offered are supportive services for conducting clinical studies. However, Medpace is an important partner for leading pharmaceutical and medical companies worldwide, benefiting from Medpace's professional and excellent planning and execution of clinical studies. Medpace's business model is based on providing high-quality clinical study services that help its customers bring innovative therapies and medications to the market. Medpace is in a key position in the global clinical research industry and can rely on a strong market position and experienced team of experts.
odotettu liikevaihto Medpace Holdings on 2,85 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Medpace Holdings on 496,04 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Medpace Holdings:n hinta-voitto-suhde (P/E) on tällä hetkellä 36,27. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Medpace Holdings-osakkeen arvostusta.
Medpace Holdings:n hinta-myynti-suhde (P/S) on tällä hetkellä 6,31. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Medpace Holdings-osakkeen arvostuskennuslukuna.
Medpace Holdings:n Eulpool-laatuscore on 7/10.
Medpace Holdings:n ISIN on US58506Q1094. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Medpace Holdings:n WKN on A2APTV. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Medpace Holdings:n ticker on MEDP. Tämä pörssinoteeraus käytetään Medpace Holdings-osakkeiden kauppaan pörssissä.
Medpace Holdings osake
Medpace Holdings vertaisryhmä
Medpace Holdings Ticker
Medpace Holdings FIGI
Kaikki tunnusluvut ja syvällinen analyysi Medpace Holdings:sta
Meidän osakeanalyysimme Medpace Holdings-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Medpace Holdings:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: